TickerFacts.

CG Oncology, Inc. (CGON): Depreciation & Amortization

Annual figures by period end, from SEC filings.

$1.45M
Year ended 2025-12-31
$2.96M
Trailing 12 months to 2026-06-30
2023-12-31: $17.0K2024-12-31: $32.0K2025-12-31: $1.45M$1.45M
2023-12-31 Depreciation & Amortization (USD) 2025-12-31
Period endedDepreciation & AmortizationChange YoYSource filing
2025-12-31$1.45Mn/m2026-02-27, From 2025-01-01
2024-12-31$32.0K+88.2%2026-02-27, From 2024-01-01
2023-12-31$17.0Kn/a2026-02-27, From 2023-01-01

Depreciation & Amortization at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedDepreciation & AmortizationChange YoY
CG Oncology, Inc. (CGON)2025-12-31$1.45Mn/m
Prime Medicine, Inc. (PRME)2025-12-31$7.32M+19.5%
CRISPR Therapeutics AG (CRSP)2025-12-31$19.48M+1.1%
Surrozen, Inc. (SRZN)2025-12-31$537.0K-62.8%
Zeo ScientifiX, Inc. (ZEOX)2025-10-31$73.0K-1.4%
DBV Technologies S.A. (DBVT)2025-12-31$2.99M+9.8%
Fate Therapeutics Inc (FATE)2025-12-31$12.90M-32.0%
Curis Inc (CRIS)2025-12-31$169.0K-16.7%
Alpha Cognition Inc. (ACOG)2025-12-31$58.6K-27.9%

Compare CGON, PRME, CRSP, SRZN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗